

Supplementary Table 1. Characteristics of Overall Salvage Regimens Identified in the Systematic Review

Category	Previous regimen	Interventions (number of intervention arms)	
Second-line, 23 studies, 47 arms	PAC fail, 15 studies, 31 arms	Bismuth quadruple (n=12)	PBTM (n=9)*, PBTA (n=2), PBMA (n=1)
		Quinolone triple (n=9)	PAL (n=8)*, PML (n=1)
		Quinolone quadruple (n=5)	Levo-bismuth (PBLA) (n=2), levo-bismuth (PBLT) (n=1), levo-sequential (PA-PML) (n=2)
		Others (n=5)	PAM (n=2), PAT (n=1), PATM (n=1), concomitant (PACM) (n=1)
	PAM fail, 1 study, 2 arms	PB+furazolidone+L (n=1), PB+furazolidone+rufloxacin (n=1)	
	PAC/M fail, 2 studies, 4 arms	Levo-bismuth (PBLA) (n=1), PBTM (n=1), PL+furazolidone (n=1), PB+furazolidone+doxycycline (n=1)	
	Triple, NS, 2 studies, 4 arms	Sequential (PA-PC+tinidazole) (n=1), PBTM (T replaced by doxycycline) (n=1), PBTM (n=1), PM+moxifloxacin (n=1)	
PBAC/M, 2 studies, 4 arms	Quintuple (PBTM+oxfloxacin) (n=1), quintuple (PBAC+tinidazole) (n=1), PBAC (n=1), PB+ofloxacin+azithromycin (n=1)		
NS, 2 studies, 5 arms	PAL (n=2), levo-sequential (PA-PML) (n=1), high dose dual (PA) (n=1), sequential (PA-PCM) (n=1)		
Third-line, 5 studies, 11 arms	PAC-PAM fail, 3 studies, 7 arms	Quinolone triple (n=5)	PA+sitafloxacin (n=2), PM+sitafloxacin (n=1), PAL (n=1), PA+gatifloxacin (n=1)
		Dual (not high dose) (n=2)	PA (n=2)
	PACM+quinolone fail, 2 studies, 4 arms	PBTM (n=1), PBMA (n=1), PB+minocycline+tinidazole (n=1), PB+minocycline+rifabutin (n=1)	
Duration comparison, 5 studies, 12 arms	PAC fail, 3 studies	PBTM, 7-day vs. 14-day, 3 studies ^a	
	PAC/M fail, 1 study	PAL, 7-day vs. 10-day, 1 study (levofloxacin 500 mg vs. 1,000 mg)	
	PAC-PAM(-sitafloxacin regimen) fail, 1 study	PA+rifabutin, 10-day vs. 14-day, 1 study	
PPI comparison, 2 studies, 4 arms	PAC-PBTM fail, 1 study	PA+rifabutin: A 1 g tid and P standard vs. double dose bid, 1 study	
	PAC fail, 1 study	PBTM: rabeprazole vs. esomeprazole, 1 study	

P, proton pump inhibitor; A, amoxicillin; C, clarithromycin; B, bismuth; T, tetracycline; M, metronidazole; L, levofloxacin; NS, not specified; tid, three times a day; bid, twice a day.

^aIncluded in the meta-analysis.